Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, is an effective treatment option for rheumatoid arthritis (RA), but its use has been associated with an increased risk of digestive events. This systematic review aimed to investigate the risk of digestive events in RA patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu-yan, Nie, Kun, Zhao, Cheng, Xu, Ming-hao, Liu, Xue-xiao, Jin, Yong-mei, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361017/
https://www.ncbi.nlm.nih.gov/pubmed/37484342
http://dx.doi.org/10.1016/j.heliyon.2023.e17002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361017/
https://www.ncbi.nlm.nih.gov/pubmed/37484342
http://dx.doi.org/10.1016/j.heliyon.2023.e17002

Ejemplares similares